Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Amylin Pharmaceuticals Stories

2013-10-23 08:28:57

INDIANAPOLIS, Oct. 23, 2013 /PRNewswire/ -- -- Worldwide revenue increased 6 percent, driven by solid growth for Cymbalta, insulins, Animal Health, Alimta, Cialis and Trajenta. -- Higher revenue and ongoing cost containment drove strong operating income growth. -- Earnings per share totaled $1.11 for the third quarter of 2013. -- 2013 earnings per share guidance narrowed to the range of $4.33 - $4.38 (reported), or $4.10 - $4.15 (non-GAAP). --...

2013-07-24 08:29:13

INDIANAPOLIS, July 24, 2013 /PRNewswire/ -- Worldwide revenue increased 6 percent as growth in key products offset lower Zyprexa revenue following patent expirations in most major markets. Cymbalta sales increased 22 percent while Cialis increased 13 percent. Higher revenue and ongoing cost containment drove strong earnings growth. Second quarter earnings per share grew to $1.11 (reported), or $1.16 (non-GAAP). 2013 earnings per share guidance range raised to $4.28 - $4.38...

2013-05-14 23:28:45

DrugRisk is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Sacramento, CA (PRWEB) May 14, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. The maker of the drug has agreed with moving the growing number of injury claims to a special federal court in California*. DrugRisk was created to improve the safety of...

2013-04-24 08:28:19

INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. Cymbalta revenue increased 19 percent while Cialis increased 11 percent. Expense controls resulted in lower SG&A, offsetting growth in R&D expense. First quarter 2013 results include income of $495 million related to the transfer to Amylin of exenatide commercial rights outside of the U.S. Tax rate comparisons...

2012-10-24 07:30:05

INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ -- Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets. Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge). Data read-outs provided a better understanding of several potential new...

2012-08-09 02:29:27

INDIANAPOLIS, Aug. 9, 2012 /PRNewswire/ -- Company will recognize income in the third quarter of 2012 of approximately $790 million (pre-tax), or approximately $.43 per share (after-tax). 2012 earnings per share guidance range on a non-GAAP basis unchanged at $3.30 - $3.40. 2012 earnings per share guidance range on a reported basis raised to $3.72 - $3.82. Company remains on track to meet or exceed its mid-term minimum financial performance goals. Eli Lilly and Company (NYSE: LLY)...

2012-07-12 06:24:31

CHICAGO, July 12, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include WellPoint Inc. (NYSE:WLP), AMERIGROUP Corporation (NYSE:AGP), Bristol-Myers Squibb Company (NYSE:BMY), Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN), and Eli Lilly & Company (NYSE:LLY). (Logo:...

2012-07-09 06:29:03

DALLAS, July 9, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) in connection with a buyout for $31.00 per share to Bristol-Myers Squibb. Concerned AMLN investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies. "Amylin's recently approved diabetes drug, Bydureon,...

2012-07-03 10:22:58

BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (Nasdaq - AMLN) relating to the proposed acquisition by Bristol-Myers Squibb Company ("Bristol-Myers"). Under the terms of the transaction, Amylin shareholders will receive only $31.00 in cash for each of Amylin stock they own. The investigation concerns possible...

2012-07-03 02:24:55

VANCOUVER, British Columbia, July 3, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Bank of America (NYSE:BAC), Amylin Pharmaceuticals (NASDAQ:AMLN), Bristol Myers Squibb (NYSE:BMY), Constellation Brands (NYSE:STZ), US Airways Group (NYSE:LCC), and Alpha Natural Resources (NYSE:ANR). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need...